Mitomycin Export Market Intelligence: India's 213 Suppliers Shipping to 103 Countries — TransData Nexus 2026

Q: Who are the top mitomycin exporters from India?

The top mitomycin exporters from India are: 1. INTAS PHARMACEUTICALS LIMITED — $2.4M (29.7% market share); 2. MYLAN LABORATORIES LIMITED — $2.4M (29.7% market share); 3. NAPROD LIFE SCIENCES PRIVATE LIMITED — $738.6K (9.1% market share); 4. INTAS PHARMACEUTICALS LTD — $558.1K (6.8% market share); 5. NAPROD LIFE SCIENCES PVT LTD — $335.8K (4.1% market share). Together they account for 79.5% of India's total mitomycin export value.

Q: What is the total export value of mitomycin from India?

The total export value of mitomycin from India is $8.2M USD, recorded across 1,333 shipment transactions from 213 active exporters to 103 destination countries. The average shipment value is $6.1K.

Q: Which countries import mitomycin from India?

India exports mitomycin to 103 countries worldwide. The top importing countries are: UNITED STATES (63.5% share, $5.2M), ALGERIA (7.5% share, $611.7K), THAILAND (5.2% share, $427.5K), JAPAN (3.9% share, $322.0K), CANADA (3.0% share, $245.8K). These five markets account for 83.2% of total export value.

Q: What is the HS code for mitomycin exports from India?

The primary HS code for mitomycin exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of mitomycin exports from India?

The average unit price for mitomycin exports from India is $13.79 USD per unit, with prices ranging from $0.01 to $311.57 depending on formulation, packaging, and order volume. The total market is valued at $8.2M across 1,333 shipments.

Q: Which ports handle mitomycin exports from India?

The primary ports for mitomycin exports from India are SAHAR AIR (25.6% of shipments), SAHAR AIR CARGO ACC (INBOM4) (19.6% of shipments), Bombay Air (7.8% of shipments), DELHI AIR (6.8% of shipments), DELHI AIR CARGO ACC (INDEL4) (5.4% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of mitomycin?

India is one of the world's leading exporters of mitomycin due to its large base of 213 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports mitomycin to 103 countries, demonstrating 53% global market coverage.

Q: What certifications do Indian mitomycin exporters need?

Indian mitomycin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import mitomycin from India?

There are 456 registered buyers importing mitomycin from India, spread across 103 countries. The repeat buyer rate is 47.4%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top mitomycin supplier from India?

INTAS PHARMACEUTICALS LIMITED is the leading mitomycin exporter from India with a market share of 29.7% and total export value of $2.4M across 46 shipments. The top 5 suppliers together control 79.5% of total export value.

Suresh Sormare

Mitomycin

India Pharmaceutical Trade Intelligence

$8.2M213 Suppliers103 CountriesHS 30049049

ExportsIndia → UNITED STATES63.5%India → ALGERIA7.5%

ImportsUNITED STATES → India$69.3K UNITED KINGDOM → India$7.0K

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: RX CROSSROADS

Mitomycin Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Mitomycin to the World

Between 2022 and 2026, India exported $8.2M worth of mitomycin across 1,333 verified shipments to 103 countries — covering 53% of world markets in the Advanced Oncology segment. The largest destination is UNITED STATES (63.5%). INTAS PHARMACEUTICALS LIMITED leads with a 29.7% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Mitomycin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Mitomycin export data snapshot — $8.2M · 213 exporters · 103 countriesTransData Nexus · Indian Customs Data

Top Mitomycin Exporters from India

213 active exporters · Ranked by export value

View all 213 →

Top Mitomycin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	INTAS PHARMACEUTICALS LIMITED	$2.4M	46	6	29.7%
2	MYLAN LABORATORIES LIMITED

Top Countries Importing Mitomycin from India

103 destination markets · Ranked by import value

All 103 countries →

Top Countries Importing Mitomycin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$5.2M	63.5%
2	ALGERIA	$611.7K	7.5%
3	THAILAND	$427.5K	5.2%
4	JAPAN	$322.0K	3.9%
5	CANADA	$245.8K	3.0%
6	VENEZUELA	$172.2K	2.1%
7	POLAND	$157.2K	1.9%
8	IRAQ	$152.2K	1.9%
9	SAUDI ARABIA	$95.2K	1.2%
10	UNITED ARAB EMIRATES	$78.4K	1.0%

UNITED STATES is India's largest mitomycin export destination, absorbing 63.5% of total exports worth $5.2M. The top 5 importing countries — UNITED STATES, ALGERIA, THAILAND, JAPAN, CANADA — together account for 83.2% of India's total mitomycin export value. The remaining 98 destination countries collectively receive the other 16.8%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Mitomycin to India?

5 origin countries · Total import value: $85.8K

India imports mitomycin from 5 countries with a combined import value of $85.8K. The largest supplier is UNITED STATES ($69.3K, 6 shipments), followed by UNITED KINGDOM and CANADA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Mitomycin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$69.3K	6	80.8%
2	UNITED KINGDOM	$7.0K	3	8.2%
3	CANADA	$5.9K	1	6.9%
4	NETHERLANDS	$2.1K	2	2.4%
5	ITALY	$1.5K	3	1.8%

UNITED STATES is the largest supplier of mitomycin to India, accounting for 80.8% of total import value. The top 5 origin countries — UNITED STATES, UNITED KINGDOM, CANADA, NETHERLANDS, ITALY — together supply 100.0% of India's mitomycin imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Mitomycin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, mitomycin is approved for various oncological indications. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for mitomycin, indicating a competitive generic market. Notably, on June 12, 2025, the FDA approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

As of March 2026, there are no active FDA import alerts specifically targeting mitomycin from Indian manufacturers. This absence suggests compliance with FDA regulations among Indian exporters. Given that 213 Indian exporters are actively involved in mitomycin exports, maintaining stringent quality standards is imperative to ensure continued market access.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products, including mitomycin. Mitomycin is authorized for use in various cancer treatments across EU member states. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates mitomycin, ensuring its safety and efficacy.

Manufacturers exporting mitomycin to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA. These standards ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use.

3WHO Essential Medicines & Global Standards

Mitomycin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The 24th edition of the list, published on September 5, 2025, continues to feature mitomycin as an essential medicine. (who.int)

Regarding pharmacopoeial standards, mitomycin is listed in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, safety, and efficacy of mitomycin across different markets.

4India Regulatory Classification

In India, mitomycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, mitomycin is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics.

For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring that the export complies with national regulations and does not adversely affect domestic availability.

5Patent & Exclusivity Status

Mitomycin's primary patents have expired, leading to the availability of generic versions in various markets. This expiration has intensified competition among manufacturers, including Indian exporters, who have capitalized on the opportunity to supply generic mitomycin globally.

6Recent Industry Developments

In June 2025, the FDA approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, reaffirming mitomycin's status as an essential medicine. (who.int)

In January 2026, the FDA issued Import Alert 89-08, concerning devices without approved PMAs or IDEs. While not directly related to mitomycin, this alert underscores the FDA's ongoing vigilance in regulating medical products.

In February 2026, the USPTO updated its Patent Center, enhancing transparency and accessibility for stakeholders monitoring patent statuses, including those related to pharmaceuticals like mitomycin.

In March 2026, the WHO launched a digital version of its Model List of Essential Medicines, facilitating easier access and reference for healthcare professionals and regulators worldwide. (who.int)

These developments reflect the dynamic regulatory and market environment surrounding mitomycin, emphasizing the importance of continuous monitoring and compliance for stakeholders involved in its production and distribution.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Mitomycin

Retail & reference prices across 9 markets vs. India FOB export price of $13.79/unit

Global Price Benchmark for Mitomycin across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$33.00	USD	Pricing data from PharmacyChecker.com indicates that the lowest price for Mitomycin 10 mg is $33.00 per injection.
United Kingdom	N/A	GBP	Specific pricing information for Mitomycin in the UK is not readily available from government sources.
Germany	N/A	EUR	Specific pricing information for Mitomycin in Germany is not readily available from government sources.
Australia	N/A

Supply Chain Risk Assessment — Mitomycin

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

The production of Mitomycin's Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs), many of which are sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing facilities, causing disruptions in the supply of KSMs. For instance, in 2018, the closure of Chinese companies impacted Indian pharmaceutical players due to supply uncertainties emerging out of China, where KSM manufacturers are located. Such events underscore the vulnerability of the Mitomycin supply chain to external factors affecting KSM availability.

2Supplier Concentration & Single-Source Risk

The Mitomycin export market from India is highly concentrated, with the top five exporters accounting for 79.5% of total exports. INTAS PHARMACEUTICALS LIMITED and MYLAN LABORATORIES LIMITED each hold a 29.7% share, indicating a significant reliance on a limited number of suppliers. This concentration poses a risk of supply disruptions if any of these key exporters face operational challenges.

Access Complete Mitomycin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,333 transactions across 103 markets.

Request Demo View Pricing

Frequently Asked Questions — Mitomycin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top mitomycin exporters from India?

The leading mitomycin exporters from India are INTAS PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, NAPROD LIFE SCIENCES PRIVATE LIMITED, and 9 others. INTAS PHARMACEUTICALS LIMITED leads with 29.7% market share ($2.4M). The top 5 suppliers together control 79.5% of total export value.

What is the total export value of mitomycin from India?

The total export value of mitomycin from India is $8.2M, recorded across 1,333 shipments from 213 active exporters to 103 countries. The average shipment value is $6.1K.

Which countries import mitomycin from India?

India exports mitomycin to 103 countries. The top importing countries are UNITED STATES (63.5%), ALGERIA (7.5%), THAILAND (5.2%), JAPAN (3.9%), CANADA (3.0%), which together account for 83.2% of total export value.

What is the HS code for mitomycin exports from India?

The primary HS code for mitomycin exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Mitomycin

Mitomycin

Top Mitomycin Exporters from India

Top Countries Importing Mitomycin from India

Who Supplies Mitomycin to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Mitomycin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Mitomycin

Supply Chain Risk Assessment — Mitomycin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Mitomycin Trade Intelligence

Frequently Asked Questions — Mitomycin Exports from India

Who are the top mitomycin exporters from India?

What is the total export value of mitomycin from India?

Which countries import mitomycin from India?

What is the HS code for mitomycin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of mitomycin exports from India?

Which ports handle mitomycin exports from India?

Why is India a leading exporter of mitomycin?

What certifications do Indian mitomycin exporters need?

How many buyers import mitomycin from India?

What is the market share of the top mitomycin exporter from India?

Analysis Methodology